Jubilant subsidiary recalls drugs in UK

Font Size

Print

Feedback

Email

Discuss

Related Articles

Pfizer’s Handa is new MD of Wyeth IndiaLower forex losses put Ranbaxy back in the blackPfizer profit up 26% on job cutsPfizer forms policies to raise standards

Mumbai: Indian pharma companies continue to be at the receiving end of tough quality scrutiny by drug regulators abroad, the latest being Jubilant Pharmaceuticals NV, the Belgium subsidiary of the Rs 3,500-crore Jubilant Organosys.

Jubilant Pharmaceuticals NV has been asked by UK Medicines & Health Regulatory Authority (MHRA), the largest drug watchdog in Europe, to recall various batches of its product, amlodipine besilate, from the UK market following “serious good manufacturing practices (GMP) deficiencies” found during an inspection of its contract manufacturer, Mumbai-based MJ Bio Pharma.

The products are distributed through Wockhardt’s UK arm. Amlodipine besilate is the copycat version of Pfizer’s $4.8-billion hypertension drug Norvasc, which went off-patent in 2007, opening the market to generic competition.

The alert, issued on June 29, asked the company to recall the drugs within 48 hours from the shelves across the UK.

The market size the recalled products could not be immediately ascertained, but Jubilant has a growing global presence, and has garnered Rs 2,177 crore revenues from international operations in FY09. The company sells mostly in the US, followed by Europe. In Europe, it had revenues of Rs 108 crore in the fourth quarter of FY09.

The company may still not be hit by a loss of reputation in the UK market, since the size of the recall is relatively small. However, the growing number of Indian companies coming under the regulatory scanner is indeed a cause of concern for all Indian generic manufacturers, experts feel.

Responding to queries from FE, a Jubilant Organosys spokesperson said, “Jubilant Pharmaceuticals NV holds a few market authorisations using MJ Bio Pharma (MJBP), which failed EU-GMP audit by UKMHRA in June 2009, and consequently, Jubilant has recalled its products: Amlodipine 5mg and 10 mg tablets from the market. However, this recall pertains to the supplies made from MJBP in 2008. The value of the products recalled is insignificant to the overall turnover of Jubilant. During 2009, the supplies of this product have been made to all customers through Jubilant’s UK MHRA approved facility at Roorkee in India.”

Jubilant shares were down 1.12% on the Bombay Stock Exchange on Wednesday at Rs 163.50. The alert comes under the class 2 drug alert. Though not as severe as class 1 recall, class 2 recalls are for products that might cause a temporary health problem, or pose slight threat of a serious nature.